SYNTHOS RESEARCH

TransDigm Group TDG

Industrials · Aerospace & Defense · Synthos Deep Dive · 2026-07-03

$1,348.49
Hold
Risk 6Growth 8Exponential 4Fair value $1360 $960–$1680

At a glance

VerdictHold — systematic Synthos tier
Price (2026-07-02)$1,348.49 · market cap ~$75.4B
Synthos scores (0–10)Downside Risk 6 · Growth Quality 8 · Exponential Potential 4
Synthos fair value (base case)~$1,360+1% · full range $960 (bear) – $1,680 (bull)
Street consensus$1,569 (high $1,871 / low $1,350; 22 Buy · 17 Hold · 0 Sell) — context, not our anchor
Valuation42× trailing EPS · 34× FY26E · 29× FY27E · 20× FY30E · EV/S 10.9× · EV/EBITDA 21.6×
Exponential Potential4/10 · Modest — ~16% forward EPS CAGR but decelerating, M&A-fuelled, in a mature niche; $75B cap limits the multibagger
TechnicalsMixed — $1,348, −16.8% off 52-wk high, above 50-DMA but below 200-DMA, RSI 70 (stretched), −11% 12-mo vs SPY +21%
ConvictionLow-Moderate — only 1 net-bullish voice, 2 reconciled claims (Invest Like the Best); verdict is fundamentals/quant-driven
Position sizingWatch-list; if bought, satellite ~1–3%, scaled on weakness
Next catalyst2026-08-04 FQ3'26 earnings (Street EPS $10.26, rev ~$2.67B)
Single biggest risk5.9× net-debt/EBITDA into a "higher-for-longer" rate world — interest expense already eats ~38% of EBIT

One-line thesis. TransDigm is a genuinely elite business — a "public private-equity firm" that buys sole-source, proprietary aerospace aftermarket parts and raises prices for decades — but the stock is up against a full 42× multiple, a stretched RSI, a heavy 5.9× debt load, and 12-month price underperformance (−11% vs SPY +21%). Great company, unexciting entry: Watch.

◆ Synthos call — Hold TDG is a solid business largely reflected at ~$1,360 — fine to keep, no reason to chase; it gets interesting again below ~$1,156.
Downside Risk (lower = safer)
6/10 · High
Low beta (0.90) & recession-resistant aftermarket — but 5.9× net-debt/EBITDA, negative equity, 42× trailing.
Growth Quality
8/10 · Very High
~16% forward EPS CAGR, 59% gross / 50% EBITDA margin, elite aftermarket ROIC & pricing power.
Exponential Potential
4/10 · Moderate
Real compounder, but M&A-fuelled and decelerating; $75B cap and mature niche cap the multibagger.
⚖ Reverse-DCF cross-check Market-implied growth ≈ 33%/yr To justify today’s $1,348, earnings would have to compound roughly 33% a year for 10 years (9% discount rate). Analysts forecast ~15%/yr, so the market is pricing in MORE than what the Street expects.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

In plain English

TransDigm makes small, boring, mission-critical airplane parts — latches, pumps, actuators, ignition systems — where it is very often the only approved supplier. Once a part is designed into a jet that flies for 30 years, the airline has to keep buying replacements from TransDigm, and TransDigm raises the price every year. That is a fantastic, cash-gushing business model, run like a buyout shop that keeps borrowing money to buy more of these little monopolies.

The catch: the stock is expensive (you pay about $42 for every $1 of annual profit), the company owes a lot of money (roughly six years of earnings-before-interest in debt), and the shares have actually gone nowhere for a year while the rest of the market climbed. Our verdict is Watch — admire the business, wait for a better price.

Here's what our three scores mean in everyday terms:

The one big worry: TransDigm's whole strategy runs on cheap debt. Its interest bill already swallows over a third of operating profit, so if rates stay high for years, the machine grinds slower.


Price & moving averages 12 months · 50 & 200-day averages · 52-week range

1,0941,2351,3771,5181,660Jul '25Sep '25Nov '25Feb '26Apr '26Jul '2652w hi $1,621Price 1,348200-DMA 1,28450-DMA 1,23352w lo $1,133

Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.

Bollinger Bands 20-day average ± 2 standard deviations

1,0501,2291,4071,5861,764Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26Price 1,34820-day avg 1,288

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

RSI (14) momentum gauge · 0–100

705030Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26RSI 63.1

Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 63.

MACD 12 / 26 / 9 · trend & momentum

0Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26MACD 28.6signal 26.5

Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.

Relative performance vs S&P 500 & its sector (XLI (sector)), set to 100 a year ago

7185100115129Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26XLI (sector) 124S&P 500 120TDG 89

Solid = TDG · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

0481215$7BFY23EPS $25$8BFY24EPS $33$9BFY25EPS $37$10BFY26EEPS $40$11BFY27EEPS $47$12BFY28EEPS $54$13BFY29EEPS $62$14BFY30EEPS $68

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$1,348.49
Market cap$75B
P/E trailing59×
P/E FY26E / FY27E34× / 29×
EV / Sales10.9×
EV / EBITDA21.6×
Gross margin59.0%
Net margin21.3%
Dividend yield12.24%
Beta0.895
52-wk range$1,133 – $1,621
RSI(14)70
50 / 200-DMA$1,233 / $1,284
12-mo return+-11% (SPY +21%)
Street target$1,569 ($1,350–$1,871)
Analyst grades22 Buy · 17 Hold · 0 Sell
FMP ratingC+
Next earnings2026-08-05

What the experts actually said 2 traceable claims on TDG · showing the highest-conviction voices

“TransDigm is a buy: a public private-equity firm acquiring niche proprietary aerospace parts with immense, expanding pricing power/margins.”
Invest Like the Bestbullishconviction 652026-05-29invest_like_the_best-wz-nbqJGzGo:41f5b4f42f
“TransDigm is in a slower cyclical patch—acquisition debt taken at 2022-era higher rates makes it sensitive to a higher-rate environment.”
Invest Like the Bestneutralconviction 552026-05-29invest_like_the_best-wz-nbqJGzGo:66934fede6

Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.

1. What it is

TransDigm Group (NYSE: TDG) is a Cleveland-based aerospace components maker, founded 1993, that operates less like a manufacturer and more like a disciplined private-equity roll-up. Its edge is a portfolio of highly engineered, proprietary, sole-source parts — roughly ~90% proprietary and a large majority sole-source — sold heavily into the commercial aftermarket, where recurring, price-insensitive replacement demand supports decades of above-inflation price increases. Fiscal year ends late September.

Revenue mix (FY2025, from filings):

The model: acquire niche proprietary-part makers, apply the "value drivers" (pricing, new business, productivity), fund it with debt, and periodically return capital via special dividends or buybacks. It has compounded revenue from ~$5.1B (FY20) to $8.83B (FY25) — much of it via M&A.

2. The expert thesis — thin coverage, so this is a quant/fundamentals call (traceable)

Honest disclosure up front: the Synthos KB has only 2 claims on TDG from 1 source (Invest Like the Best), net 1 bullish voice. This is not a high-breadth conviction name like our flagship healthcare positions. The verdict below is therefore fundamentals- and quant-driven, with the expert claims used only as corroboration, not as an anchor.

Honest composite note. With a single voice on both sides of the ledger, there is no panel consensus to lean on. We treat the business quality as real and well-documented, but the stock call rests on valuation, leverage, and price action — where the picture is far less compelling than the franchise.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

Score0–10The read
Downside Risk (lower = safer)6 · Above-averageLow beta (0.90) and a recession-resistant aftermarket cushion the downside, but 5.9× net-debt/EBITDA, negative book equity (from special dividends), 42× trailing EPS, and interest eating ~38% of EBIT stack real financial risk.
Growth Quality8 · High~16% forward EPS CAGR, 59% gross / 50%+ EBITDA margin, ROIC ~14.5% well above cost of capital, and a genuinely durable sole-source moat. Docked from 9 because much of the growth is bought, not organic (organic sales +9–11%).
Exponential Potential4 · ModestA superb compounder, but a decelerating, M&A-fuelled one in a mature niche. Revenue growth is easing from the post-COVID recovery pace, and a $75B cap in a finite parts market caps the multibagger.

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.

CaseKey assumptionsFair value
BullAftermarket stays hot, air-traffic cycle extends, accretive M&A continues, rates ease. FY27E EPS beats to ~$49 (vs $47 cons); market keeps paying a premium ~34×.~$1,680 (+25%)
Base (our anchor)Estimates roughly hit — FY27E EPS ~$47; a durable mid-teens compounder with 50% EBITDA margin earns a ~29× multiple, in line with its own recent history.~$1,360 (+1%)
BearAir-traffic/aftermarket softens, rate stays high and interest compounds, an acquisition disappoints. FY27E EPS misses to ~$42; multiple de-rates to ~23×.~$960 (−29%)

Synthos fair value = the base case, ~$1,360 (+1%), with the full $960–$1,680 span as the honest range. Our base sits well below the Street's $1,569 consensus: the sell side extrapolates the multiple and the M&A engine more generously than we will at 5.9× leverage into a higher-for-longer rate backdrop. Notably the Street's low target ($1,350) is essentially today's price — the whole sell-side range is skewed upward. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). TDG is a best-in-class compounder that is not accelerating:

Exponential Potential: Modest (4/10). Own TDG for durable mid-teens earnings compounding and elite capital allocation — not for a fast multibagger. The very leverage that has powered the historical multibagger is now a governor.

5. Financials (real numbers — FMP annual/quarterly)

6. Valuation — priced in or room?

TDG is not cheap on any trailing metric (42× EPS, 10.9× sales, 21.6× EV/EBITDA). The bull's defense is the same as for any quality compounder: earnings grow into the multiple — forward P/E compresses to 34× (FY26E) → 29× (FY27E) → 20× (FY30E) if estimates hit. But two things temper that:

1. EV/EBITDA is the honest lens here given the leverage — and at 21.6× TTM, TDG is already at the rich end of its own history, so the multiple offers little cushion.

2. The stock has de-rated in price terms already — −11% over 12 months while earnings grew — which tells you the market has been paying down the premium, not expanding it.

Our ~$1,360 base fair value (+1%) says the shares are roughly fairly priced for a great business — attractive to hold, unexciting to initiate. Street targets (context): consensus $1,569, high $1,871, low $1,350 — we are deliberately below the Street because we underwrite the leverage and rate sensitivity more conservatively. Not a value buy, and — unlike a true compounder-at-a-discount — not obviously a growth buy at today's price either.

7. Technicals (from the tech block)

8. Moat & competitive position

TDG's moat is unusually clean: sole-source, proprietary parts designed into aircraft that fly for decades, sold into a fragmented aftermarket where the airline has no approved alternative and switching means re-certification. That yields pricing power few industrials can match — the source of the 59% gross / 50%+ EBITDA margins. The durable risks are (a) OEM/regulator pushback on aftermarket pricing (a perennial political target), (b) the air-traffic cycle (aftermarket demand tracks flight hours), and (c) the leverage that funds the strategy. The moat is real; the stock's risk is financial and valuation, not competitive displacement.

Peer set (FMP-provided, market cap): General Dynamics $101B, Quanta $100B, Vertiv $115B, Johnson Controls $86B, Emerson $78B, Northrop Grumman $78B, Illinois Tool Works $78B, Cintas $73B, L3Harris $56B, Thomson Reuters $39B. Note: FMP's peer list is a broad industrials/A&D basket, not a like-for-like aftermarket comp — TDG's true comps are Heico and the aftermarket units of the majors. TDG commands a premium multiple within the group, justified by its margin profile and aftermarket mix.

9. Management, capital allocation & guidance

10. Catalysts & what to watch

Thesis tripwires (what would change the call): two quarters of organic aftermarket deceleration; EBITDA-As-Defined margin slipping below ~50%; interest coverage falling toward ~2×; or an out-of-pattern, richly priced acquisition.

11. Key risks

12. Verdict, position sizing & monitoring

Watch. TransDigm is one of the highest-quality business models in the S&P 500 — sole-source aerospace parts, 59% gross / 50%+ EBITDA margins, elite capital allocation, and a management raising guidance on base-business strength. But as a stock at $1,348, the setup is unexciting: a full 42× / 21.6× EV/EBITDA multiple, 5.9× net leverage into a higher-for-longer rate world, a stretched 70 RSI after a bounce, price below the 200-DMA, and a full year of underperformance (−11% vs SPY +21%). Our base fair value (~$1,360) is essentially flat to spot, and our conservative underwriting of the leverage puts us well below the Street's $1,569. Great company, wait for a better price.


Provenance & disclosures